Busulfan Alternatives Compared
Busulfan | Gleevec | Tasigna |
|
---|
Busulfan | Gleevec (imatinib) | Tasigna (nilotinib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Bone Marrow Transplantation, Thrombocythemia, Chronic Myelogenous Leukemia. busulfan may also be used for purposes not listed in this medication guide. |
Prescription only
Gleevec is an oral tyrosine kinase inhibitor that may be used to treat Ph+CML, Ph+ALL, and some other conditions. It may cause fluid retention, nausea, pain, headache, or blood abnormalities and... View more |
Prescription only
Prescribed for Chronic Myelogenous Leukemia. Tasigna may also be used for purposes not listed in this medication guide. |
||||||||||||||||
More about Busulfan | More about Gleevec (imatinib) | More about Tasigna (nilotinib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Busulfan has an average rating of 10.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Gleevec has an average rating of 8.6 out of 10 from a total of 37 ratings on Drugs.com. 88% of reviewers reported a positive effect, while 6% reported a negative effect. |
Tasigna has an average rating of 8.0 out of 10 from a total of 30 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 11% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: busulfan side effects in more detail. |
See also: Gleevec side effects in more detail. |
See also: Tasigna side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Gleevec prices |
View all Tasigna prices |
||||||||||||||||
Dosage Forms Available | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Busulfex, Myleran |
N/A |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
N/A |
40 hours |
17 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 278 drugs are known to interact with busulfan:
|
A total of 730 drugs are known to interact with Gleevec:
|
A total of 770 drugs are known to interact with Tasigna:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
June 26, 1954 |
May 10, 2001 |
October 29, 2007 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.